Best GLP-1 Drug for Weight Loss in 2026: A Data-Driven Comparison

You have done your research. You know GLP-1 drugs work. Now the question is which one — and the honest answer is that it depends on factors the headline efficacy numbers do not show you.

This is not a list of “top picks.” It is an evidence-grounded comparison of the four approved GLP-1 options available in the US in 2026, the first head-to-head trial data between the two market leaders, and a framework for thinking through which drug fits your actual situation rather than a population average.

The GLP-1 landscape in 2026

Four GLP-1 receptor agonist drugs are FDA-approved for weight management in the US as of May 2026.

Semaglutide (Wegovy) — the first once-weekly injectable to reach this indication. Approved June 2021 for adults with BMI ≥30, or BMI ≥27 with at least one weight-related condition (see our GLP-1 eligibility criteria guide for full label details). A subcutaneous injection, titrated from 0.25 mg up to the 2.4 mg maintenance dose over approximately 16 weeks. The Wegovy dose escalation guide explains what to expect at each titration step.

Tirzepatide (Zepbound) — approved November 2023. Also a once-weekly subcutaneous injection; titrated from 2.5 mg to a maximum of 15 mg. The mechanism differs from semaglutide in a clinically meaningful way — more on this below.

Oral semaglutide (Wegovy tablet, 50 mg) — approved in late 2024 for weight management. A daily oral formulation of the same molecule as Wegovy, requiring a specific dosing protocol: take on an empty stomach with no more than 4 oz of water, wait 30 minutes before eating, drinking, or taking other medications. The food/water restriction is the core tradeoff against the convenience of no injections.

Orforglipron (Foundayo) — FDA-approved April 1, 2026, making it the newest entry and the first oral non-peptide GLP-1 for weight loss. Unlike oral semaglutide, it has no food or water restrictions. Available via LillyDirect at $149/month regardless of dose tier.

Several older GLP-1 options — including liraglutide (Saxenda) and dulaglutide (Trulicity) — remain approved for diabetes but are rarely prescribed for weight management in 2026 given the superior efficacy of the newer agents.

Tirzepatide vs semaglutide: what the head-to-head trial found

Until 2024, comparing tirzepatide and semaglutide required reading across separate trials conducted in different populations under different conditions. That changed with SURMOUNT-5.

SURMOUNT-5 was a phase 3b, randomised, double-blind, head-to-head trial enrolling 751 adults with obesity, no diabetes. Both drugs were titrated to maximum tolerated dose over 36 weeks, then maintained through 72 weeks. Results published in the New England Journal of Medicine:

• Tirzepatide: mean body weight change of −20.2% (95% CI: −21.4 to −19.1)
• Semaglutide: mean body weight change of −13.7% (95% CI: −14.9 to −12.6)
• The gap: 6.5 percentage points, representing roughly 47% more mean weight loss for tirzepatide

Secondary measures followed the same direction. Waist circumference reduction: −18.4 cm for tirzepatide vs −13.0 cm for semaglutide. At every weight-loss threshold tested — ≥10%, ≥15%, ≥20%, ≥25% of starting weight — tirzepatide patients were more likely to achieve it.

Why does tirzepatide outperform? The mechanism is the key difference. Semaglutide is a selective GLP-1 receptor agonist. Tirzepatide activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP receptors are present in adipose tissue and appear to regulate lipid storage and energy expenditure; their co-activation with GLP-1 receptors produces what researchers describe as synergistic effects on fat mobilisation. The dual mechanism is why tirzepatide is classified as a “dual agonist” rather than simply a GLP-1. For a deeper head-to-head on the two molecules, see our tirzepatide vs semaglutide comparison.

The practical implication: at equal access and equal tolerability, the clinical data consistently favours tirzepatide for weight loss outcomes.

What the trial numbers actually mean for you

A question that comes up constantly — and fairly — is whether a population average of −20% translates to an individual experience. The answer is: not reliably.

SURMOUNT-5 enrolled patients who reached maximum tolerated dose and stayed there for over a year. In real-world prescribing, that does not happen for everyone. Gastrointestinal side effects — nausea, diarrhoea, constipation, vomiting — are concentrated during dose escalation and push a meaningful proportion of patients to plateau at lower doses than the trial maximum. At lower doses, the efficacy gap between tirzepatide and semaglutide narrows.

Observational studies of US electronic health records show average weight loss of 8–15% at 12 months for both drugs. The people hitting −20% in SURMOUNT-5 were carefully selected, carefully monitored, and held at maximum dose.

Individual response also varies in ways that trial averages erase. The primary thing GLP-1s address is “food noise” — the constant low-level preoccupation with food that most people taking these drugs describe as dissolving within weeks. Some people’s food noise responds more strongly to one mechanism than the other; some who plateau on semaglutide respond well after switching to tirzepatide, and vice versa.

The honest framing: tirzepatide is the higher-expected-value bet for weight loss if both drugs are equally accessible and affordable. But the drug you can actually afford, access, and stay on consistently will outperform the drug with better trial numbers that you take inconsistently or stop taking due to side effects.

When semaglutide is the better choice

Semaglutide is not a consolation prize. For many patients in 2026, it is the right drug — not because the efficacy numbers are better, but because the access and cost situation makes tirzepatide impractical for their situation.

Your insurance covers semaglutide but not tirzepatide. Commercial insurance coverage of GLP-1s for weight management varies by plan, employer, and state. If your plan covers Wegovy but not Zepbound, the effective cost difference may be thousands of dollars per year.

You have previously tried tirzepatide and tolerated it poorly. Individual GI tolerance differs between drugs. Some patients who experience significant nausea or diarrhoea on tirzepatide tolerate semaglutide substantially better. Side effect profiles overlap, but individual response to the specific formulations can diverge.

You want the longer safety track record. Wegovy has been on the market since 2021, and the SELECT trial — which showed a 20% reduction in major adverse cardiovascular events in patients with established CVD — was conducted with semaglutide. Tirzepatide has SURMOUNT-MMO and SURPASS-CVOT cardiovascular data, but the follow-up period is shorter.

You are already well-established on semaglutide and progressing toward your goal. Switching mid-treatment carries risks: re-titration, a new side-effect adjustment period, potential supply disruptions. If semaglutide is working, the calculus for switching is not automatic.

When tirzepatide is the better choice

If both drugs are comparably accessible and your primary goal is maximum weight loss, the head-to-head data favours tirzepatide.

You have both obesity and type 2 diabetes. Tirzepatide (Mounjaro) has one of the strongest A1c-reduction profiles of any T2D medication. If weight loss and glycaemic control are both goals, tirzepatide addresses both more effectively. Your prescriber may be able to obtain Mounjaro under the T2D indication if Zepbound coverage is denied.

You are paying cash-pay via manufacturer-direct and cost is comparable. LillyDirect charges $299/month for lower Zepbound dose tiers (2.5 mg and 5 mg), compared to NovoCare at $349/month for Wegovy. At these price points, tirzepatide is the higher-efficacy choice at lower or equal cost.

You have not previously tried a GLP-1 and both drugs are available at comparable cost. Starting from scratch with no prior tolerability data, the efficacy evidence supports tirzepatide if access is equal.

You are starting at a higher body weight where every percentage point of reduction matters. For patients where reaching a lower weight is medically significant — for surgical candidacy, cardiovascular risk, joint health — the additional efficacy of tirzepatide is clinically meaningful, not just statistical.

The new oral option: orforglipron (Foundayo)

A category-relevant development in 2026 is the approval of orforglipron (Foundayo) on April 1, 2026. It warrants discussion in any 2026 GLP-1 comparison because it changes the “injectable only” assumption that has defined this class.

Orforglipron is a non-peptide small-molecule GLP-1 receptor agonist — the first of its kind to reach approval. Being a small molecule allows it to be absorbed orally without the food restriction that oral semaglutide requires. The once-daily dosing has no food or water timing requirements.

Efficacy from the ATTAIN-1 trial (36 mg, 72 weeks): −12.4% mean body weight change vs −0.9% for placebo. That is below semaglutide (−14.9% in STEP-1) and substantially below tirzepatide (−22.5% at max dose in SURMOUNT-1), but in a different access category: a daily pill at $149/month with no injection and no food timing requirement.

One FDA label note: patients taking oral contraceptives should use backup contraception for 30 days after initiating orforglipron and after each dose escalation, due to reduced contraceptive absorption.

For detail on orforglipron’s approval data and mechanism, see our Orforglipron (Foundayo) guide.

What each drug actually costs in 2026

As of May 2026:

Medicare does not cover GLP-1s for obesity as of May 2026, though the Medicare GLP-1 Bridge program (effective July 1, 2026) will cover Zepbound KwikPen at $50/month for qualifying seniors with obesity and cardiovascular disease.

Manufacturer-direct programs require no insurance. LillyDirect and NovoCare are cash-pay options that bypass the insurance prior authorisation process entirely. Your own prescriber can write for these programs — you do not need to use a specific telehealth provider.

For full detail on each manufacturer program, see our guides to NovoCare Wegovy enrollment and LillyDirect Zepbound enrollment.

How to pick: three questions to answer first

1. What will this drug actually cost you? Check your insurance formulary before your prescriber appointment. The question is not which drug has better trial numbers; it is which drug you will still be taking in 12 months. Cost is the primary adherence risk. Our how to get a GLP-1 prescription guide walks through the full process from first appointment to filled Rx.

2. What outcome are you trying to achieve, and does efficacy gap matter at your starting point? If your goal is 10–15% weight loss, semaglutide’s trial outcomes reliably reach that territory. If you are targeting 20%+ or have a higher starting BMI where further loss is medically significant, tirzepatide’s stronger efficacy profile matters. Discuss the difference with your prescriber in the context of your specific starting weight and goals.

3. Do you have a prior tolerability record? If you have tried one GLP-1 and stopped due to intolerable GI side effects, that is a data point worth bringing to the conversation. Individual GI response does not always track between semaglutide and tirzepatide formulations.

What is not a useful standalone question: “Which drug is best?” The trials say tirzepatide wins on average. Your situation may not be average. The answers to these three questions — discussed with your prescriber, who knows your full medical picture — determine your right choice.

The pipeline: what comes after tirzepatide

For context, two drugs in late-stage development are producing outcomes that exceed current options:

Retatrutide (Lilly, triple GLP-1/GIP/glucagon agonist): Phase 2 data showed up to −28.7% body weight reduction. Phase 3 ongoing; NDA submission expected Q4 2026.

CagriSema (Novo Nordisk, semaglutide + cagrilintide): NDA filed December 2025. Phase 3 data: −23% mean weight loss at 68 weeks. Advisory committee review expected Q3–Q4 2026.

Neither is available now, and approval timelines are uncertain. The drugs covered in this article are what you can access today. We will update this page as FDA review of both drugs proceeds.

All pricing cited as of May 2026, sourced from manufacturer program pages. Pricing changes without notice. Clinical trial data cited is from published literature; sources listed above. This article does not constitute medical advice; prescribing decisions should be made with your healthcare provider based on your individual medical history, insurance situation, and health goals.

Related: Wegovy vs Zepbound · Tirzepatide Cash Price 2026 · GLP-1 Prior Authorization Appeal Guide · Orforglipron (Foundayo)